Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07506941
Starting soon Observational

Study of Functional Decline and Care Pathways in Neurosurgical Patients Over 65 Years of Age

NCT07506941 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Toulouse
Phase
Observational
Started
2026-04-01
Last updated
2026-04-02

Condition(s) studied

Ageing and Geriatric Health

Study summary

The GENEUS 1 study addresses this gap by characterizing the real-world profiles, outcomes, and care pathways of adults aged 65 years and older hospitalized in neurosurgery across France, Spain, and Portugal. This project represents the first multicentre, transnational initiative to integrate geriatric principles into neurosurgical practice and to evaluate both clinical and economic outcomes in this population.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: Age ≥ 65 years at the time of admission Admission to a neurosurgery department in one of the participating centres (France, Spain, or Portugal), Affiliation with a national health-insurance or equivalent system Feasibility of follow-up at 3 months, Consent/non-opposition for the study Exclusion Criteria: Terminal illness (neurosurgical or not) with an estimated life expectancy of \< 3 months. Loss of autonomy prior to admission, established as ADL \< 3. For a patient admitted to the emergency hospital, ask him (or his caregiver) about his functional abilities before his condition deteriorated. Legal protection status (guardianship, trusteeship, or judicial protection) when such status prevents lawful consent or non-opposition. Participation in another interventional clinical study whose procedures or follow-up could interfere with GENEUS 1 objectives or endpoints. Severe cognitive or communication impairment

Primary outcome measure(s)

  • The evolution of functional autonomy between baseline and 3 months post-discharge — between baseline and 3-month after discharge
    The change is measured using validated geriatric scale Basic Activities of Daily Living Functional decline will be defined as any clinically significant decrease in ADL score compared with baseline. The change will be expressed both as a continuous variable (score variation) and as a categorical outcome (improved / stable / declined autonomy). This criterion captures the short-term functional trajectory of older adults after a neurosurgical hospitalization and serves as the main indicator of care effectiveness and adaptation to geriatric needs.

Trial sites (6)

FacilityCityRegionStatus
Limoges University Hospital Limoges France
CUF Descobertas Lisbon Portugal
ULS Santa Maria Lisbon Portugal
Hospital General Universitario Alicante Alicante Spain
Complexo Hospitalario De Ourense Ourense Spain
Navarrabiomed Pamplona Spain

More University Hospital, Toulouse trials in France

Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia Recruiting
Pilot Study to Establish a Repertoire of Megakaryocyte Markers, Quantifiable by Spectral Flow Cytometry, in Bone Marrow and Circulating in Patients Undergoing Cardiac Surgery for Bypass Grafting Starting soon
Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes Starting soon
Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome Recruiting
Home-based Cognitive Strategy Training for Daily Living in Adults With Chronic Stroke Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07506941 on ClinicalTrials.gov ↗ ← All trials in France